> ## Content Index
> Fetch the complete content index at: https://www.elenapintea.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Swiss vs EU pharmacovigilance: what's the same, what's different
- URL: https://www.elenapintea.com/swiss-vs-eu-pharmacovigilance-whats-the-same-whats-different/
- Published: 2026-10-14T17:29:44.000Z
- Updated: 2026-11-19T16:24:22.000Z
- Description: Switzerland sits in the middle of Europe but outside the European Union. For pharmacovigilance, that creates a system that looks familiar to anyone trained on EU rules, yet has its own authority, its own reporting routes and its own local obligations.
- Author: Elena Pintea
- Tags: Swiss Regulatory Requirements

Switzerland sits in the middle of Europe but outside the European Union. For pharmacovigilance, that creates a system that looks familiar to anyone trained on EU rules, yet has its own authority, its own reporting routes and its own local obligations.

This article compares the two systems from the perspective of a local safety function in a Swiss affiliate. It draws on my regulatory and drug safety training at the University of Basel and on reporting adverse reactions in Swiss pharmacy practice.

### What is shared: the ICH foundation

Both systems are built on the same international standards. That is good news for anyone moving between them.

- **Definitions and expedited reporting principles** follow ICH E2A and E2D (International Council for Harmonisation \[ICH\], 1994, 2003).
- **Electronic transmission of individual cases** uses the ICH E2B format (European Medicines Agency \[EMA\], 2017).
- **Medical coding** uses MedDRA (Brown et al., 1999).
- **Periodic benefit-risk evaluation** follows the PBRER format of ICH E2C(R2) (ICH, 2012).
- **Pharmacovigilance planning** follows ICH E2E, the basis of risk management plans (ICH, 2004).

A safety professional who understands these standards can work in either system with relatively little adjustment.

### What is different: authority and infrastructure

| Area                            | European Union                                                                                                                           | Switzerland                                                                                                                |
| ------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------- |
| Competent authority             | National authorities plus the EMA, with PRAC for safety assessment                                                                       | Swissmedic as the single national authority                                                                                |
| Case database                   | EudraVigilance                                                                                                                           | Swissmedic's own systems, including the ElViS reporting portal                                                             |
| Responsible person              | Qualified Person for Pharmacovigilance (QPPV), resident in the EU/EEA (Directive 2001/83/EC, 2001)                                       | A designated person responsible for pharmacovigilance under Swiss law                                                      |
| Legal basis                     | EU Directive 2001/83/EC and Regulation 726/2004, detailed in GVP modules (Directive 2001/83/EC, 2001; Regulation (EC) No 726/2004, 2004) | HMG and VAM, with Swissmedic guidance (Medicinal Products Ordinance \[VAM\], 2018; Therapeutic Products Act \[TPA\], 2000) |
| Language of product information | National languages of each member state                                                                                                  | German, French and Italian                                                                                                 |

Because Switzerland is not part of EudraVigilance, Swiss cases must be reported to Swissmedic separately (VAM, 2018). Companies operating in both markets maintain parallel reporting processes.

### Local responsibilities of a Swiss affiliate

In practice, a local safety function in Switzerland carries a set of recurring tasks:

1. **Case intake and reporting:** collecting adverse event information from Swiss sources and ensuring compliant, timely submission to Swissmedic and the company's global safety database.
2. **Local literature review:** screening Swiss medical journals and publications that may not be covered by global literature searches.
3. **Safety communications:** preparing and distributing direct healthcare professional communications in coordination with Swissmedic, usually in three languages.
4. **Risk minimisation:** implementing additional risk minimisation measures, such as educational materials, adapted to the Swiss healthcare system.
5. **Local procedures:** keeping SOPs and working instructions aligned with current Swiss requirements.
6. **Training:** teaching local colleagues and business partners how to recognise and forward adverse events.
7. **Inspection readiness:** maintaining documentation that can withstand Swissmedic inspections and internal audits.

### Clinical trials: a separate set of rules

Pharmacovigilance in clinical trials follows the Clinical Trials Ordinance (KlinV) under the Human Research Act (Clinical Trials Ordinance \[KlinV\], 2013). Serious adverse events and suspected unexpected serious adverse reactions (SUSARs) must be reported to the competent ethics committee and, for medicinal product trials, to Swissmedic, within defined timelines.

Annual safety reporting follows the development safety update report (DSUR) concept of ICH E2F (ICH, 2010).

### Practical consequences for global companies

The differences create real work for local safety teams:

- **Dual timelines:** Swiss reporting clocks run independently from EU clocks.
- **Local approvals:** safety communications and label changes require Swissmedic review, even when the EU has already acted.
- **Translation and adaptation:** materials must be accurate in German, French and Italian.
- **Cross-functional embedding:** commercial, medical, market access and patient support activities must all include pharmacovigilance requirements.

That last point is often underestimated. Patient support programmes, market research and social media projects can all generate adverse event information. A local safety function reviews these activities to make sure that information is captured.

### What a pharmacy background brings

I have experienced the Swiss system from the reporter's side. I know what a Swiss healthcare professional sees, how product information is used in practice and how safety communications reach the pharmacy.

That perspective helps in designing communications and training that actually work for the people receiving them. It also helps when following up cases with Swiss pharmacists and doctors, because I understand their constraints.

### Key takeaways

- Swiss and EU pharmacovigilance share the same ICH foundations.
- Switzerland has its own authority, database, legal basis and language requirements.
- Local safety functions handle reporting, literature review, communications, training and inspection readiness for the Swiss market.

### References

Brown, E. G., Wood, L., & Wood, S. (1999). The Medical Dictionary for Regulatory Activities (MedDRA). *Drug Safety, 20*(2), 109–117\. https://doi.org/10.2165/00002018-199920020-00002

Clinical Trials Ordinance \[KlinV\] of 20 September 2013, SR 810.305 (Switzerland). https://www.fedlex.admin.ch

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. (2001). *Official Journal of the European Communities*, L 311, 67–128.

European Medicines Agency. (2017). *Guideline on good pharmacovigilance practices (GVP): Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2)*. https://www.ema.europa.eu

International Council for Harmonisation. (1994). *Clinical safety data management: Definitions and standards for expedited reporting E2A*. https://www.ich.org

International Council for Harmonisation. (2003). *Post-approval safety data management: Definitions and standards for expedited reporting E2D*. https://www.ich.org

International Council for Harmonisation. (2004). *Pharmacovigilance planning E2E*. https://www.ich.org

International Council for Harmonisation. (2010). *Development safety update report E2F*. https://www.ich.org

International Council for Harmonisation. (2012). *Periodic benefit-risk evaluation report (PBRER) E2C(R2)*. https://www.ich.org

Medicinal Products Ordinance \[VAM\] of 21 September 2018, SR 812.212.21 (Switzerland). https://www.fedlex.admin.ch

Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. (2004). *Official Journal of the European Union*, L 136, 1–33.

Therapeutic Products Act \[TPA\] of 15 December 2000, SR 812.21 (Switzerland). https://www.fedlex.admin.ch